PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

BACKGROUND: HER2 targeted therapies including trastuzumab and more recently lapatinib have significantly improved the prognosis for HER2 positive breast cancer patients. However, resistance to these agents is a significant clinical problem. Although several mechanisms have been proposed for resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, Martina SJ, Browne, Brigid C, Conlon, Neil T, O’Brien, Neil A, Slamon, Dennis J, Henry, Michael, Meleady, Paula, Clynes, Martin, Dowling, Paul, Crown, John, O’Donovan, Norma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230643/
https://www.ncbi.nlm.nih.gov/pubmed/24958351
http://dx.doi.org/10.1186/1476-4598-13-157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230643/
https://www.ncbi.nlm.nih.gov/pubmed/24958351
http://dx.doi.org/10.1186/1476-4598-13-157

Ejemplares similares